C4 Therapeutics (CCCC) Current Assets (2019 - 2026)

C4 Therapeutics has reported Current Assets for 8 years, with the latest figure at $245.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 5.52% year-over-year to $245.4 million; the trailing twelve-month figure through Mar 2026 stood at $245.4 million (up 5.52% YoY), and the FY2025 full-year result was $258.1 million, changed 0.13% from the prior year.
• Current Assets for Q1 2026 stood at $245.4 million, down from $258.1 million in the prior quarter.
• The five-year high for Current Assets was $325.5 million in Q3 2022, with the low at $206.9 million in Q3 2025.
• Average Current Assets over 5 years is $266.8 million, with a median of $273.2 million recorded in 2024.
• Year-over-year, Current Assets slumped 33.34% in 2022 and grew 22.15% in 2024.
• Tracing CCCC's Current Assets over 5 years: stood at $287.6 million in 2022, then decreased by 5.69% to $271.2 million in 2023, then retreated by 4.95% to $257.8 million in 2024, then increased by 0.13% to $258.1 million in 2025, then dropped by 4.94% to $245.4 million in 2026.
• The last three Current Assets figures came in at $245.4 million (Q1 2026), $258.1 million (Q4 2025), and $206.9 million (Q3 2025), per Business Quant data.

Peer Comparison